AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30093503 — intervention group
Group type: EXPERIMENTAL
Intervention: Repotrectinib (TPX-0005)
Number of subjects: 0
Study 30093511 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c ≥6.5% for diabetes diagnosis
Number of subjects: 581
Study 30093511 — intervention group
Group type: COMPARATOR
Intervention: HbA1c <5.7% for normal category
Number of subjects: 581
Study 30093511 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c 5.5%-6.1% for pre-diabetes diagnosis
Number of subjects: 581
Study 30093511 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c 6.1% for type 2 diabetes diagnosis
Number of subjects: 581
Study 30093511 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c 5.5%-6.1%
Number of subjects: 581
Study 30093518 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild anaemia at any time during delivery
Number of subjects: 72750
Study 30093518 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe anaemia at any time during pregnancy
Number of subjects: 72750
Study 30093518 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight at any time during pregnancy
Number of subjects: 72750
Study 30093518 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaemia and underweight co-existing
Number of subjects: 72750
Study 30093518 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity/overweight during pregnancy
Number of subjects: 72750
Study 30093520 — intervention group
Group type: EXPERIMENTAL
Intervention: PROBE questionnaire
Number of subjects: 916
Study 30093531 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (TDZ) 25 mg every 6 hours for 21 days
Number of subjects: 13
Study 30093531 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (TDZ) 50 mg every 6 hours for 21 days
Number of subjects: 13
Study 30093531 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (TDZ) 100 mg every 6 hours for 21 days
Number of subjects: 13
Study 30093531 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (TDZ) with hydroxyurea
Number of subjects: 13
Study 30093531 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (TDZ) alone
Number of subjects: 13
Study 30093866 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with vitamin D (10 μg/day)
Number of subjects: 122
Study 30093866 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 122
Study 30094070 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic (4-cycle schedule, ≤24 doses)
Number of subjects: 24
Study 30094070 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic
Number of subjects: 24
Study 30094213 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery (RA) graft
Number of subjects: 529
Study 30094213 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein graft (SVG)
Number of subjects: 529
Study 30094213 — intervention group
Group type: EXPERIMENTAL
Intervention: Major adverse cardiac events (MACE)
Number of subjects: 529
Study 30094213 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-free cardiac survival
Number of subjects: 529
Study 30094347 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity consultation based on motivational interview technique
Number of subjects: 0
Study 30094347 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30094730 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS)
Number of subjects: 45
Study 30094930 — intervention group
Group type: EXPERIMENTAL
Intervention: HbSβ genotype
Number of subjects: 0
Study 30094930 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30095337 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral MRgFUS pallidotomy
Number of subjects: 10
Study 30095339 — intervention group
Group type: EXPERIMENTAL
Intervention: GPCirA volume, presence of hydrocephalus or partial thrombosis (PT) of the aneurysm, degree of brainstem displacement (∆MT)
Number of subjects: 30
Study 30095339 — intervention group
Group type: EXPERIMENTAL
Intervention: GPCirA volume
Number of subjects: 30
Study 30095576 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased vitamin D dosage according to NACFF guidelines
Number of subjects: 90
Study 30095603 — intervention group
Group type: EXPERIMENTAL
Intervention: XEN gel implant surgery (combined XEN+cataract surgery or standalone XEN surgery)
Number of subjects: 100
Study 30095672 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial analyses including examination of alpha and beta diversity, correlational analyses of bacterial abundance, and machine learning to identify bacterial patterns.
Number of subjects: 48
Study 30095761 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based quality indicators for postpartum hemorrhage care
Number of subjects: 398
Study 30095761 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management of postpartum hemorrhage
Number of subjects: 398
Study 30095761 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of vital signs
Number of subjects: 398
Study 30095761 — intervention group
Group type: EXPERIMENTAL
Intervention: Video recordings
Number of subjects: 398
Study 30095761 — intervention group
Group type: EXPERIMENTAL
Intervention: Local postpartum hemorrhage protocol
Number of subjects: 398
Study 30095761 — intervention group
Group type: EXPERIMENTAL
Intervention: Team trainings
Number of subjects: 398
Study 30095761 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patient identification and type of hospital
Number of subjects: 398
Study 30096071 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine (YF-17D strain)
Number of subjects: 71
Study 30096144 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived Competence in Diabetes Scale (PCDS)
Number of subjects: 0
Study 30096144 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Care Climate Questionnaire (HCCQ)
Number of subjects: 0
Study 30096144 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Self-Regulation Questionnaire (TSRQ)
Number of subjects: 0
Study 30096144 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term complications (specifically foot-related problems)
Number of subjects: 0
Study 30096144 — intervention group
Group type: EXPERIMENTAL
Intervention: Being female
Number of subjects: 0
Study 30097064 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodiafiltration (HDF)
Number of subjects: 177
Study 30097064 — intervention group
Group type: COMPARATOR
Intervention: Conventional haemodialysis (HD)
Number of subjects: 177
Study 30097433 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation CAR T cells
Number of subjects: 15
Study 30097477 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical-onset FRDA
Number of subjects: 650
Study 30097706 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Analgesia (TEA) with levobupivacaine bolus
Number of subjects: 18
Study 30097706 — intervention group
Group type: COMPARATOR
Intervention: Correction of blood pressure in 7 patients
Number of subjects: 18
Study 30097769 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic-naive first-episode psychosis (AN-FEP) patients
Number of subjects: 270
Study 30097769 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 270
Study 30097769 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic-naive first-episode psychosis (AN-FEP) female patients
Number of subjects: 270
Study 30097995 — intervention group
Group type: COMPARATOR
Intervention: Insulin Degludec
Number of subjects: 0
Study 30098189 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI participants
Number of subjects: 71
Study 30098189 — intervention group
Group type: COMPARATOR
Intervention: Normal participants
Number of subjects: 71
Study 30098305 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of meat
Number of subjects: 89
Study 30098305 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of vegetables
Number of subjects: 89
Study 30098602 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion with irradiation and prolonged storage time
Number of subjects: 0
Study 30098602 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 0
Study 30098602 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC metabolomic profiles
Number of subjects: 0
Study 30098602 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) for measuring intestinal oxygenation
Number of subjects: 0
Study 30098602 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfused RBC characteristics (irradiation and metabolism)
Number of subjects: 0
Study 30098648 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch 2 mg/24 hours (single dose)
Number of subjects: 24
Study 30098648 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch 2 mg/24 hours (multiple doses)
Number of subjects: 24
Study 30098648 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch 4 mg/24 hours (multiple doses)
Number of subjects: 24
Study 30098648 — intervention group
Group type: COMPARATOR
Intervention: Rotigotine transdermal patch (cold-chain PR2.1.1)
Number of subjects: 24
Study 30098648 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (2 mg/24 hours)
Number of subjects: 24
Study 30098677 — intervention group
Group type: EXPERIMENTAL
Intervention: ANCHOR Anal HSIL Health-Related Symptom Index
Number of subjects: 45
Study 30098677 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept elicitation interviews
Number of subjects: 45
Study 30098677 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive interviews
Number of subjects: 45
Study 30098707 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15mg administered twice daily for 90 days
Number of subjects: 7
Study 30099150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive mobilization under analgesic gas (equimolar mixture of oxygen and nitrous oxide)
Number of subjects: 0
Study 30099150 — intervention group
Group type: COMPARATOR
Intervention: Intensive mobilization under placebo gas (sham gas administration)
Number of subjects: 0
Study 30099150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive mobilization under analgesic gas
Number of subjects: 0
Study 30099150 — intervention group
Group type: COMPARATOR
Intervention: Intensive mobilization under placebo gas
Number of subjects: 0
Study 30099268 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg) infusion over 40 min
Number of subjects: 128
Study 30099350 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment for eight weeks
Number of subjects: 15
Study 30099350 — intervention group
Group type: COMPARATOR
Intervention: Control period (no treatment)
Number of subjects: 15
Study 30099396 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic distal gastrectomy (LDG) after neoadjuvant chemotherapy
Number of subjects: 96
Study 30099396 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG) after neoadjuvant chemotherapy
Number of subjects: 96
Study 30099397 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) - intravenous infusion of 10 mL (1 g) immediately followed by three identical infusions over 8 hours (total dose of 4 g over 24 hours)
Number of subjects: 500
Study 30099397 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) - intravenous infusion of 40 mL over 24 hours
Number of subjects: 500
Study 30099401 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternity waiting homes (MWHs) intervention in 20 health facility clusters
Number of subjects: 2400
Study 30099401 — intervention group
Group type: COMPARATOR
Intervention: Standard of care for waiting mothers in 20 control clusters
Number of subjects: 2400
Study 30099532 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline-dilated aortic root dimension (ARD) defined by z-score (Ao-Z > 0.80)
Number of subjects: 8573
Study 30099532 — intervention group
Group type: COMPARATOR
Intervention: Non-dilated aortic root dimension (ARD)
Number of subjects: 8573
Study 30099641 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab administration
Number of subjects: 411
Study 30099641 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 411
Study 30099818 — intervention group
Group type: EXPERIMENTAL
Intervention: Sym004 6 mg/kg/wk
Number of subjects: 51
Study 30099818 — intervention group
Group type: EXPERIMENTAL
Intervention: Sym004 9 mg/kg loading/6 mg/kg/wk
Number of subjects: 51
Study 30099818 — intervention group
Group type: EXPERIMENTAL
Intervention: Sym004 12 mg/kg/wk
Number of subjects: 51
Study 30099818 — intervention group
Group type: EXPERIMENTAL
Intervention: Sym004 18 mg/kg biweekly
Number of subjects: 51
Study 30099818 — intervention group
Group type: EXPERIMENTAL
Intervention: Sym004 at the dose recommended from Part A (12 mg/kg/wk) in Part B
Number of subjects: 51
Study 30099922 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to start systemic therapy
Number of subjects: 0
Study 30099922 — intervention group
Group type: COMPARATOR
Intervention: Younger age
Number of subjects: 0
Study 30099922 — intervention group
Group type: COMPARATOR
Intervention: Higher ECOG performance score
Number of subjects: 0
Study 30099922 — intervention group
Group type: COMPARATOR
Intervention: More than one site of metastatic disease
Number of subjects: 0
Study 30099922 — intervention group
Group type: COMPARATOR
Intervention: Colon site of the primary tumor
Number of subjects: 0
Study 30099922 — intervention group
Group type: COMPARATOR
Intervention: No oncologic surgery to the primary tumor
Number of subjects: 0
Study 30099922 — intervention group
Group type: COMPARATOR
Intervention: No concurrent bevacizumab administration
Number of subjects: 0
Study 30100725 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide
Number of subjects: 86
Study 30100725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 30101328 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean-marked increase group
Number of subjects: 13327
Study 30101328 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-marked increase group
Number of subjects: 13327
Study 30101328 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean-marked increase group (adjusted for current BMI)
Number of subjects: 13327
Study 30101328 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-marked increase group (adjusted for current BMI)
Number of subjects: 13327
Study 30101330 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding for 0-6 months
Number of subjects: 2987
Study 30101330 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding for 6-12 months
Number of subjects: 2987
Study 30101330 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding for >12 months
Number of subjects: 2987
Study 30101330 — intervention group
Group type: COMPARATOR
Intervention: No breastfeeding
Number of subjects: 2987
Study 30101330 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding >0-6 months
Number of subjects: 2987
Study 30101330 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding >6-12 months
Number of subjects: 2987
Study 30101330 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding >12-18 months
Number of subjects: 2987
Study 30101330 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding >18-24 months
Number of subjects: 2987
Study 30101330 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding >24-36 months
Number of subjects: 2987
Study 30101351 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intake of riboflavin
Number of subjects: 5186
Study 30101351 — intervention group
Group type: COMPARATOR
Intervention: Dietary intake of one-carbon metabolism nutrients
Number of subjects: 5186
Study 30101387 — intervention group
Group type: EXPERIMENTAL
Intervention: BGJ398 daily 3 weeks on, 1 week off (dose range: 25 - 75 mg)
Number of subjects: 16
Study 30101387 — intervention group
Group type: EXPERIMENTAL
Intervention: BGJ398 daily 1 week on, 3 weeks off (dose range: 75 - 100 mg)
Number of subjects: 16
Study 30101387 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BGJ398 and imatinib
Number of subjects: 16
Study 30101412 — intervention group
Group type: EXPERIMENTAL
Intervention: MDRO pneumonia
Number of subjects: 652
Study 30101412 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid suppression therapy
Number of subjects: 652
Study 30101412 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 652
Study 30101412 — intervention group
Group type: EXPERIMENTAL
Intervention: History of MDRO infection
Number of subjects: 652
Study 30101412 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate initial antimicrobial selection
Number of subjects: 652
Study 30101572 — intervention group
Group type: EXPERIMENTAL
Intervention: PEDI-EAT-10 score > 12
Number of subjects: 254
Study 30101572 — intervention group
Group type: EXPERIMENTAL
Intervention: PEDI-EAT-10 in children with airway aspiration (PAS > 5)
Number of subjects: 254
Study 30101572 — intervention group
Group type: COMPARATOR
Intervention: PEDI-EAT-10 in children without aspiration (PAS < 6)
Number of subjects: 254
Study 30101572 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between PEDI-EAT-10 and PAS scores
Number of subjects: 254
Study 30102205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT) followed by gemcitabine, dexamethasone, and cisplatin (GDP)
Number of subjects: 40
Study 30102705 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rifamycins and clofazimine, specific dosage and duration not provided
Number of subjects: 0
Study 30102705 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30102789 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide treatment for 2 years
Number of subjects: 0
Study 30102789 — intervention group
Group type: COMPARATOR
Intervention: Dual-energy X-ray absorptiometric (DXA) measurement
Number of subjects: 0
Study 30102967 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 20-60 mg/day
Number of subjects: 485
Study 30102967 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 80-120 mg/day
Number of subjects: 485
Study 30102967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study 30103071 — intervention group
Group type: EXPERIMENTAL
Intervention: Micra transcatheter pacemaker
Number of subjects: 1817
Study 30103071 — intervention group
Group type: COMPARATOR
Intervention: Micra transcatheter pacemaker (PAR)
Number of subjects: 1817
Study 30103342 — intervention group
Group type: EXPERIMENTAL
Intervention: SIGNAL trial (NCT02481674)
Number of subjects: 0
Study 30103342 — intervention group
Group type: EXPERIMENTAL
Intervention: CREST-E trial (NCT00712426)
Number of subjects: 0
Study 30103695 — intervention group
Group type: EXPERIMENTAL
Intervention: Swiss Multiple Sclerosis Registry (SMSR)
Number of subjects: 1600
Study 30103979 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-directed medical therapies (ACE inhibitors, ARBs, β blockers, MRAs) at recommended doses
Number of subjects: 5276
Study 30103979 — intervention group
Group type: EXPERIMENTAL
Intervention: Uptake of guideline-directed medical therapies
Number of subjects: 5276
Study 30103979 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year composite outcome of all-cause death or admittance to hospital because of heart failure
Number of subjects: 5276
Study 30104007 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib and topotecan
Number of subjects: 0
Study 30104186 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered lifestyle intervention (yearlong digital intervention guided by health coaches)
Number of subjects: 82
Study 30104186 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline RBANS score
Number of subjects: 82
Study 30104186 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SCD-9 score
Number of subjects: 82
Study 30104186 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Generalized Anxiety Disorder 7-item scale score
Number of subjects: 82
Study 30104186 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Patient Health Questionnaire 9-item score
Number of subjects: 82
Study 30104298 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients (women)
Number of subjects: 1365
Study 30104298 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients (men)
Number of subjects: 1365
Study 30104298 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients
Number of subjects: 1365
Study 30104311 — intervention group
Group type: EXPERIMENTAL
Intervention: Job dissatisfaction
Number of subjects: 1906
Study 30104311 — intervention group
Group type: COMPARATOR
Intervention: Mandatory accreditation attitudes
Number of subjects: 1906
Study 30104718 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy and autologous stem cell transplantation
Number of subjects: 0
Study 30104894 — intervention group
Group type: EXPERIMENTAL
Intervention: duloxetine 60 mg/day
Number of subjects: 93
Study 30104987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic motivation (IM)
Number of subjects: 0
Study 30104987 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect
Number of subjects: 0
Study 30104987 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Number of subjects: 0
Study 30105052 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive Radiotherapy (RT)
Number of subjects: 0
Study 30105052 — intervention group
Group type: COMPARATOR
Intervention: Imiquimod
Number of subjects: 0
Study 30105163 — intervention group
Group type: EXPERIMENTAL
Intervention: CCSVI intervention (specific details not provided)
Number of subjects: 63
Study 30105416 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive ventilation
Number of subjects: 1604
Study 30105416 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Number of subjects: 1604
Study 30105416 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy
Number of subjects: 1604
Study 30105416 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard oxygen
Number of subjects: 1604
Study 30105416 — intervention group
Group type: EXPERIMENTAL
Intervention: No oxygen
Number of subjects: 1604
Study 30105416 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of hypoxemia
Number of subjects: 1604